Table 1.
Baseline patient demographic and clinical overactive bladder characteristics
| Mirabegron initiators (N = 613) | Antimuscarinic initiators (N = 901) | |
|---|---|---|
| Demographic characteristics | ||
| Age at enrollment in years | ||
| Mean (SD) | 62.6 (14.6) | 62.0 (14.3) |
| Median (min, max) | 65.0 (19, 93) | 64.0 (18, 93) |
| Female sex, n (%) | 424 (69.2) | 689 (76.5) |
| BMI in kg/m2, mean (SD)a | 30.1 (7.1) | 30.4 (7.2) |
| Country, n (%) | ||
| USA | 390 (63.6) | 808 (89.7) |
| Canada | 223 (36.4) | 93 (10.3) |
| Race, n (%) | ||
| White | 544 (88.7) | 776 (86.1) |
| Black/African American | 41 (6.7) | 86 (9.5) |
| Other | 19 (3.1) | 28 (3.1) |
| Unknown/not available | 9 (1.5) | 11 (1.2) |
| Ethnicity, n (%)b | ||
| Non-Hispanic | 427 (69.7) | 425 (47.2) |
| Hispanic | 93 (15.2) | 435 (48.3) |
| French Canadian | 18 (2.9) | 11 (1.2) |
| Unknown/not available | 75 (12.2) | 30 (3.3) |
| Employed full-time, n (%) | 178 (29.0) | 214 (23.8) |
| US drug coverage, n (%)c | ||
| Private | 164 (42.1) | 222 (27.5) |
| Medicare | 169 (43.3) | 375 (46.4) |
| Medicaid | 38 (9.7) | 106 (13.1) |
| No insurance | 5 (1.3) | 67 (8.3) |
| Other | 14 (3.6) | 38 (4.7) |
| Canadian drug coverage, n (%)c | ||
| Private | 110 (49.3) | 39 (41.9) |
| Provincial (public)—open coverage | 56 (25.1) | 12 (12.9) |
| Provincial (public)—with coverage criteria | 40 (17.9) | 38 (40.9) |
| Clinical OAB characteristics | ||
| Time since OAB diagnosis in months | ||
| Mean (SD) | 49.3 (73.6) | 41.0 (67.7) |
| Median (min, max) | 20.3 (0, 610) | 15.0 (0, 579) |
| Medical specialty of HCP who made OAB diagnosis, n (%) | ||
| Primary care | 237 (38.7) | 465 (51.6) |
| Urology | 302 (49.3) | 352 (39.1) |
| Gynecology | 48 (7.8) | 55 (6.1) |
| Other | 26 (4.2) | 29 (3.2) |
| OAB with incontinence, n (%) | 436 (71.1) | 719 (79.8) |
| Stress or mixed urinary incontinence, n (%)d | 314 (72.0) | 611 (85.0) |
| Status of using pads, n (%) | ||
| In the past | 27 (4.4) | 27 (3.0) |
| Currently | 289 (47.1) | 503 (55.8) |
| Never | 264 (43.1) | 350 (38.8) |
| Unknown | 33 (5.4) | 21 (2.3) |
| Number of pads used per weeke | ||
| Mean (SD) | 15.9 (11.7) | 20.8 (12.1) |
| Median (min, max) | 14.0 (1.0, 84.0) | 21.0 (1.0, 70.0) |
| OAB treatment history, n (%) | ||
| No medication in past 12 months | 435 (71.0) | 732 (81.2) |
| ≥ 1 medication in past 12 months | 178 (29.0) | 169 (18.8) |
| Use of complementary/supportive OAB therapies, n (%) | 121 (19.7) | 131 (14.5) |
BMI body mass index, HCP healthcare provider, OAB overactive bladder, SD standard deviation
aNot available for one patient in the antimuscarinic initiator group
bAll categories are mutually exclusive
cPercentages calculated among US and Canadian patients separately
dMirabegron initiators, n = 436; antimuscarinic initiators, n = 719
eCurrent pad users only